<?xml version="1.0" encoding="UTF-8"?>
<p>Our trial has strengths due to its appropriate size in the phase II context, and its direct prospective randomization to conventional tac/mtx 
 <italic>vs</italic>. two novel bort-based GvHD prophylaxis regimens. Concerns regarding open-label treatment assignment are ameliorated by the minimal dropout rate and the mITT analysis to further avoid bias, while the 'hard' endpoints of GvHD, NRM, relapse and survival additionally obviate assessment bias concerns.
</p>
